Ardelyx(ARDX)
搜索文档
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
Newsfilter· 2024-07-02 19:00
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patien ...
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
GlobeNewswire News Room· 2024-07-02 19:00
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patie ...
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
Newsfilter· 2024-06-28 20:17
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference, currentl ...
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
GlobeNewswire News Room· 2024-06-28 20:17
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference, current ...
3 Promising Penny Stocks for the Most Astute Investors
Investor Place· 2024-06-24 19:30
Even though they are among the riskiest stocks on the market, investing in some penny stocks can mean a lot of profits. In times of economic uncertainty, penny stock investment can be a lifesaver for investors. In this article, you’ll learn more about three of the most promising penny stocks to buy on the market and what makes them fantastic portfolio additions going into the second half of the year. Let’s dive right in.Ardelyx (ARDX)Source: MacroEcon / Shutterstock.comArdelyx (NASDAQ:ARDX) is a biopharmace ...
3 Stocks Under $10 With the Potential to Make You a Millionaire
Investor Place· 2024-06-16 18:17
Buying stocks that can make you millions is any investor’s dream. That is why some investors consider micro-cap or small-cap stocks trading under $10. Doing so lets them buy into the business and potentially make a killing if their thesis is right. But it is also a double-edged sword. When you get it wrong, losses can magnify. That is why it is important to screen for companies now, not only on price but also for significant improvements in the business, like revenue and earnings growth, to help qualify the ...
Ardelyx, Inc. Reports Employment Inducement Grants
GlobeNewswire News Room· 2024-05-31 04:02
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-executive employee ...
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
globenewswire.com· 2024-05-22 20:02
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York ...
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
Newsfilter· 2024-05-22 20:02
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York ...
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
Newsfilter· 2024-05-21 20:02
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data supporting additional positive clinical observations of IBSRELA® (tenapanor) was presented at the 2024 Digestive Disease Week Conference (DDW), currently taking place in Washington, D.C. IBSRELA is a first-in-class treatment that is appro ...